Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies

MLA

Ahmed Kandeil, et al. “Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies.” Vaccines, vol. 9, no. 3, Mar. 2021, p. 214. EBSCOhost, https://doi.org/10.3390/vaccines9030214.

APA

Ahmed Kandeil, Ahmed Mostafa, Rehab R. Hegazy, Rabeh El-Shesheny, Ahmed El Taweel, Mokhtar R. Gomaa, Mahmoud Shehata, Marawan A. Elbaset, Ahmed E. Kayed, Sara H. Mahmoud, Yassmin Moatasim, Omnia Kutkat, Noha N. Yassen, Marwa E. Shabana, Mohamed GabAllah, Mina Nabil Kamel, Noura M. Abo Shama, Mohamed El Sayes, Amira N. Ahmed, … Mohamed A. Ali. (2021). Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies. Vaccines, 9(3), 214. https://doi.org/10.3390/vaccines9030214

Chicago

Ahmed Kandeil, Ahmed Mostafa, Rehab R. Hegazy, Rabeh El-Shesheny, Ahmed El Taweel, Mokhtar R. Gomaa, Mahmoud Shehata, et al. 2021. “Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies.” Vaccines 9 (3): 214. doi:10.3390/vaccines9030214.